Monitoring glioblastoma extracellular vesicle evolution using a nanodiagnostic platform to detect glioma stem cells driving recurrent disease
Science Advances · 2026
DOI: 10.1126/sciadv.adt2804 ↗At a glance
Journal article in Science Advances, 2026. Written by Zhen Zhang and 13 co-authors. Institution: Australian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, Brisbane, QLD 4072, Australia. Major MEDLINE topics: Neoplastic Stem Cells, Extracellular Vesicles, Glioblastoma, Brain Neoplasms. Cited 5 times so far (Crossref); 75 references. The full text is freely available in PubMed Central. Funded by: Australian Research Council, National Health and Medical Research Council, China Scholarship Council.
Abstract (original language)
Assessing therapeutic response in glioblastoma (GBM) is a major factor limiting the clinical development of effective therapies. The intracranial location limits serial biopsies and only provides an intermittent view of the tumor molecular profile from the initial resection. Liquid biopsy techniques, specifically small extracellular vesicle (sEV) analysis, have the potential to overcome these limitations by providing a window into the brain using peripheral blood. To address the need for monitoring tumor evolution and therapeutic resistance, we developed a GBM biomarker panel (ATPase subunit beta-2, excitatory amino acid transporter 2, CD24, CD44, CD133, and epidermal growth factor receptor) for multiplexed profiling of sEVs using an advanced GBM Extracellular Vesicle Monitoring Phenotypic Analyzer Chip. We successfully tracked patient response to treatment by monitoring changes in glioma stem cell markers on circulating sEVs. We propose that these results provide a strong rationale for using GBM sEVs as a serial monitoring tool in the future clinical management of patients with GBM.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Australian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, Brisbane, QLD 4072, Australia.
- School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle, Newcastle, NSW 2308, Australia.
- Mark Hughes Foundation Centre for Brain Cancer Research, University of Newcastle, Newcastle, NSW 2308, Australia.
- Hunter Medical Research Institute, New Lambton Heights, Newcastle, NSW 2305, Australia.
- Key Laboratory of OptoElectronic Science and Technology for Medicine, Ministry of Education, Fujian Provincial Key Laboratory for Photonics Technology, Fujian Normal University, Fuzhou 350007, China.
- Cancer Research Department, QIMR Berghofer Medical Research Institute, Sid Faithfull Brain Cancer Laboratory, Brisbane, QLD 4006, Australia.
ORCID profiles: Zhen Zhang, Richard J Lobb, Paul Tooney, Jing Wang, Rebecca Lane, Quan Zhou, Xueming Niu, Sam Faulkner, Bryan W Day, Matt Trau
Funding
- Australian Research Council
- National Health and Medical Research Council
- China Scholarship Council
- Mark Hughes Foundation
Cite
APA
Zhang, Z., Lobb, R. J., Tooney, P., Wang, J., Lane, R., Zhou, Q., Niu, X., Faulkner, S., Al-Iedani, O., Day, B. W., Puttick, S., Rose, S., Fay, M., & Trau, M. (2026). Monitoring glioblastoma extracellular vesicle evolution using a nanodiagnostic platform to detect glioma stem cells driving recurrent disease. Science Advances. https://doi.org/10.1126/sciadv.adt2804
Vancouver
Zhang Z, Lobb RJ, Tooney P, Wang J, Lane R, Zhou Q, et al. Monitoring glioblastoma extracellular vesicle evolution using a nanodiagnostic platform to detect glioma stem cells driving recurrent disease. Science Advances. 2026. doi:10.1126/sciadv.adt2804
BibTeX
@article{Zhang2026,
author = {Zhang, Zhen and Lobb, Richard J and Tooney, Paul and Wang, Jing and Lane, Rebecca and Zhou, Quan and Niu, Xueming and Faulkner, Sam and Al-Iedani, Oun and Day, Bryan W and Puttick, Simon and Rose, Stephen and Fay, Mike and Trau, Matt},
title = {Monitoring glioblastoma extracellular vesicle evolution using a nanodiagnostic platform to detect glioma stem cells driving recurrent disease},
journal = {Science Advances},
year = {2026},
doi = {10.1126/sciadv.adt2804}
}
EUVIMED